Oslo, Norway, November 4, 2025 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that the United States
Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,462,898,
entitled, "Method For Selecting Neoepitopes".

Nykode is positioning VB10.NEO as a leading individualized neoantigen therapy,
building on experience with an established manufacturing supply chain and a
proprietary neoantigen target selection algorithm proven to drive immune
responses in two clinical trials.

The newly issued patent relates to Nykode's proprietary NeoSELECT(TM) platform
which is used for the selection of neoantigens for the company's fully
individualized neoantigen-based therapy, VB10.NEO. The 20-year expiration date
of this patent is September 27, 2039. Related patents were previously granted to
the company in Australia, China, Israel, Japan and Russia. 

The new U.S. patent complements last year's U.S. patent describing the company's
individualized neoantigen therapy VB10.NEO.

Michael Engsig, CEO of Nykode, said, "This patent underscores Nykode's continued
innovation and leadership in the field of individualized cancer immunotherapy.
Expanding our IP portfolio remains a cornerstone of our strategy to strengthen
our leading position and further advance truly individualized cancer treatments
for patients."


About VB10.NEO
VB10.NEO is a proprietary individualized neoantigen therapy in development for
the treatment of locally advanced or metastatic solid tumors. The product is
designed to be produced on-demand based on each patient's unique neoantigen
profile, identified through Nykode's AI-powered NeoSELECTTM platform, which
integrates individual patient multiomics data to select the most immunogenic
neoantigens. Neoantigens are proteins generated by tumor-specific mutations not
present in normal tissues and are thus an attractive target for cancer
immunotherapy as they may be recognized as foreign by the immune system.

Nykode has evaluated VB10.NEO in two Phase 1 clinical trials, VB N-01 and VB
N-02. VB N-01 was a first-in-human study in patients with advanced solid tumors,
designed to assess safety, feasibility, and immunogenicity of VB10.NEO in
combination with standard-of-care treatment, including checkpoint inhibitors. VB
N-02 was a Phase 1b study conducted in heavily pre-treated patients with
advanced solid tumors (median 5 prior lines of treatment), aiming to further
optimize dose and regimen in combination with the checkpoint inhibitor
atezolizumab (Tecentriq®).


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of late-line r/m
cervical cancer. Abi-suva is currently being further developed in head and neck
cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been
investigated in two trials with more than 10 different indications. 

Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
Head of Investor Relations, Alexandra Deschner
Nykode Therapeutics ASA 
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway